Scientists pool resources to create first joint pancreatic cancer research group
The Vrije Universiteit Brussel (VUB), Université libre de Bruxelles, UZ Brussel and Erasmus Hospital/Institut Jules Bordet have launched Belgium’s first joint pancreatic cancer research group.
The Brussels Pancreatic Cancer Team (BruPaCT) aims to ensure more structural collaboration, shared use of patient samples and access to high-tech infrastructure.
Pancreatic cancer remains one of the most deadly cancer types. Only 10 per cent of patients survive five years after diagnosis and the number of diagnoses increases every year. By integrating research and sharing resources, BruPaCT aims to accelerate the development of new treatments and strategies.
"Because the need among patients is so great, we have to think bigger and act faster"
“We do not sufficiently understand the fundamental biology of both healthy and tumorous pancreatic gland tissue. So it is logical for us to join forces to bring that research into the clinic,” said Professor Ilse Rooman, head of BruPaCT for VUB.
“Because the need among patients is so great, we have to think bigger and act faster. It would be a shame not to pool our knowledge and resources.”
The researchers will combine predictive models based on artificial intelligence with advanced molecular profiling to create personalised pancreatic cancer treatment.
BruPaCT focuses on several key areas in the fight against the disease: tumour initiation and progression, tumour and tissue profiling, innovative treatments, surgical advances and early detection programmes.
By pooling their resources, the group also strengthens its ability to attract research funds and expand international cooperation.
Illustration © BELGA PHOTO DAVID STOCKMAN
Related news
